Continuing Education Activity

Vibrio vulnificus, a gram-negative bacterium within the Vibrio genus, represents an increasingly urgent public health concern as global temperatures rise and marine ecosystems shift. The pathogen thrives in warm, brackish waters and infects humans primarily through contaminated seafood or open wounds exposed to seawater. Climate change, expanding geographic distribution, and emerging multidrug resistance have heightened the global burden of Vibrio vulnificus infections. This activity reviews the recognition, diagnosis, and treatment of V vulnificus, focusing on its increasing prevalence. Participants will gain an understanding of the bacterium’s transmission and its potential to cause infections ranging from mild gastroenteritis to rapidly progressive necrotizing fasciitis and sepsis, with mortality rates reaching up to 50%. Timely intervention, including early antibiotic therapy and surgical debridement, is critical to improving outcomes, especially among immunocompromised or hepatically compromised patients.

This course explores evidence-based strategies for early diagnosis, appropriate antimicrobial selection, and timely surgical management of Vibrio vulnificus infections. Differentiating clinical presentations of similar diagnoses, rapid diagnostic techniques, and implementation of sepsis protocols are also discussed. Emphasis will also be placed on the emerging challenge of antibiotic resistance and its impact on treatment decisions. This activity for healthcare professionals is designed to enhance the learner's competence in identifying Vibrio vulnificus infections, performing the recommended evaluation, and implementing an appropriate interprofessional approach to manage this condition, thereby improving patient outcomes amid evolving environmental and antimicrobial resistance challenges.

Objectives:

• Assess characteristic clinical features of Vibrio vulnificus infections.
• Identify predisposing conditions predicting poor outcomes in Vibrio vulnificus infection.
• Implement appropriate diagnostic protocols, including specimen collection and rapid PCR assays, to confirm Vibrio vulnificus infection.
• Coordinate timely interventions among the interprofessional team to improve patient outcomes and reduce mortality.

Introduction

Vibrio vulnificus, a gram-negative bacterium and pathogenic member of the Vibrio genus that includes V cholerae and V parahaemolyticus, thrives in warm marine environments. Rising ocean temperatures have allowed the organism to extend its range into more northern waters. Global climate change and associated weather events continue to drive increases in the pathogen’s prevalence, transmission, and virulence.[1] By 2081, projections indicate that Vibrio vulnificus may inhabit every eastern coastal region of the United States.[2]

Transmission of V vulnificus commonly occurs through consumption of contaminated seafood or exposure of open wounds to infected water. The infection manifests across a broad clinical spectrum, from mild gastrointestinal illness to severe necrotizing skin infections. Vibrio vulnificus accounts for the highest number of seafood-related fatalities in the United States, with death often occurring within 24 to 48 hours after symptom onset.[3][4] Mortality ranges from 18% to 50%, and annual treatment costs approach 28 million dollars.[2] As the prevalence and infection rate of Vibrio vulnificus expand geographically, multidrug resistance is emerging, exerting a significant global impact.[2][5]

Etiology

Vibrio vulnificus is a resident of marine environments, eg, estuaries, rivers, deltas, shorelines, and ocean waters. V vulnificus enters the food chain by taking up residence in the stomachs of shellfish, primarily oysters, and the intestines of fish. The bacilli infect human hosts either through contaminated seafood or via direct wound contact with contaminated water or seafood.[4] Presentations of V vulnificus infections include generalized sepsis, wound infection, and gastroenteritis. Ingestion of the bacilli can result in self-limiting enteritis in 10% to 15% of cases or can proceed to sepsis.

Primary sepsis accounts for about 60% of all cases seen, and the overall death rate for this presentation is 50%. Gastrointestinal symptoms may precede sepsis or may be completely absent. The portal for bacteremia is thought to be the small intestine or colon. Infection of wounds with the bacilli is found in approximately 25% of Vibrio vulnificus cases. Open wounds exposed to contaminated water can be colonized by bacilli, leading to a severe reaction, including cellulitis and bullae, and may rapidly progress to necrotizing fasciitis with myonecrosis. The overall mortality rate for V vulnificus wound infection approximates 25% but rises to 54% in patients with underlying hepatic disease.[6][7]

Epidemiology

Called the "microbial barometer of climate change," the Vibrio vulnificus pathogen thrives in warm, moderately salinated water, and its degradation of chitin is important to the marine ecosystem. The bacteria may exist independently or be hosted by invertebrates, eg, crustaceans and shellfish, in which they may concentrate and thus be more infectious to consumers.[8] Water with salt content between 15 and 25 parts per thousand, and areas with increased chlorophyll are most hospitable for V vulnificus, and areas with subtropical monsoon-type climates are particularly prone to their proliferation.[8] 

The summer months have higher incidence rates of disease, and the countries with the most documented cases of V vulnificus are the United States, South Korea, Taiwan, Japan, and Mexico, but increasing numbers of cases have been noted in numerous countries. Disease in the northern hemisphere predominates. One study found that V vulnificus prevalence in shellfish at Mexican coastal seafood markets was 32%, and that 8% of European seafood was affected. In the United States, Vibrio vulnificus accounts for a large share of the cost of seafood-related disease, and the season of peak infectivity has lengthened. Areas that previously reported very few infections, eg, Rhode Island, Connecticut, and New York, reported fatalities in 2024. Florida reported outbreaks after 2 major hurricanes in 2023 and 2024.[1][9]

Vibrio vulnificus is responsible for most human deaths from water and seafood-related deaths in the United States, 65% of which are from seafood ingestion.[10] Between 1988 and 2018, V vulnificus infections in the United States increased 8-fold, including areas where infection was previously rare, coinciding with rising water temperatures across Massachusetts, New Hampshire, and Maine. Notably, the hypersalinity along the West Coast creates suboptimal conditions for bacteria. Infections are also increasing globally, driven by rising water temperatures and population density.[1]

Infection rates from Vibrio vulnificus remain relatively low; however, when infection occurs, progression is rapid and accounts for the second-highest number of Vibrio-related deaths worldwide, following cholera.[1] Individuals with preexisting conditions face the greatest risk of severe disease.[11][12] Healthy persons often experience minimal clinical consequences, while those with underlying disorders have a markedly higher likelihood of developing sepsis. Patients with hepatitis, cirrhosis, hemochromatosis, diabetes, malignancies, renal disease, HIV, or other forms of immunocompromise represent 80% to 90% of all V vulnificus sepsis cases.

Even moderate alcohol consumption has been associated with an elevated risk of infection following exposure to the bacterium.[7][13] Males experience infection more frequently than females, and individuals over 40 face increased susceptibility. This demographic pattern likely reflects the higher prevalence of liver disease among older men. Mortality rates can reach 50%. No validated data-driven disease prediction model currently exists, aside from general environmental models that forecast bacterial presence without assessing specific disease risk.[14]

Vibrio vulnificus exhibits exceptional adaptability and possesses numerous virulence factors, including the vcgC gene, various toxins, and antimicrobial secretion systems, eg, T6SS1, as well as biofilm formation and flagella. The bacterium is divided into 2 major genetic lineages distinguished by virulence-associated genes, although no direct correlation between lineage and clinical severity has been established. The organism demonstrates significant genetic diversity and rapid evolution, supporting its broad adaptability. Recent research suggests that migratory birds may now function as reservoirs for Vibrio vulnificus.[15]

Global warming has been strongly correlated with the increasing prevalence and virulence of Vibrio vulnificus, driven by rising sea surface temperatures and the melting of polar ice caps, which elevate water salinity.[7][16] Climate change amplifies bacterial growth and vector distribution, producing severe outbreaks in endemic regions and new cases in previously unaffected areas.[1] Extreme weather events heighten exposure risk by bringing humans and pathogens into closer contact. The mixture of salt and fresh water during storms, combined with increased algal proliferation, creates ideal conditions for bacterial growth. In 2022, following widespread flooding from category 4 Hurricane Ian, Florida reported 74 V vulnificus infections and 17 deaths, with 50% of fatalities occurring within a week of the storm.[10] Similarly, in September 2024, category 4 Hurricane Helene produced comparable flooding and additional outbreaks, totaling 77 cases and 15 deaths—figures well above predicted regional estimates. Population density, advanced age, and delayed disaster response further contributed to these poststorm infection surges.[1][17]

Pathophysiology

The morphology of Vibrio vulnificus contributes significantly to its virulence. Structurally, V vulnificus is a flagellated motile halophilic bacillus, and the bacterium utilizes several factors to increase virulence and infectivity, including capsular polysaccharides, proteases, and hemolysins to evade the immune system and acquire iron. If transmitted via consumption of contaminated seafood, the bacteria are introduced into the gastrointestinal system. Once in the stomach, the bacteria produce lysine decarboxylase, which neutralizes acid by breaking down lysine into cadaverine. Through this mechanism, the bacteria can proliferate. In the small intestine, the pathogen utilizes a nitrate regulatory protein that aids adaptation to an anaerobic environment. Glucose is used as a substrate during this proliferative phase.[2] V vulnificus can evade immune mechanisms through resistance to antimicrobial peptides, including defensins and cathelicidins, that disrupt bacterial cell membranes and deactivate toxins.[18]

Main exotoxins of V vulnificus include VVH, MARTX, and protease VVP.[2] VVH binds to host cells, frequently red blood cells, endothelium, mast cells, or macrophages, forming membrane pores, invading and compromising the immune response, while upregulating proinflammatory cytokines. Once in the intestine, the bacteria can penetrate the epithelial barrier and migrate into the bloodstream, secreting bradykinin and increasing vascular permeability. MARTX also works to dismantle cell structure and function through several mechanisms, ultimately lysing host cells, siphoning cellular nutrients, suppressing cellular defenses, and upregulating proinflammatory cytokines, resulting in marked systemic inflammation.[19] VVP activates prothrombin, degrades structural proteins, and facilitates invasion of surrounding tissue by producing bradykinin, increasing vascular permeability, and destroying intestinal epithelial wall integrity. Many additional bacterial components contribute to communication, metabolism, pathogenicity, and gene expression.[20]

The capsular polysaccharides resist host gastric acid and trigger the release of host cytokines, eg, tumor necrosis factor, interleukin-8, and interleukin-6, while blocking complement activation, inhibiting opsonization, and promoting proinflammatory cytokines. Bacterial pili facilitate attachment to host cells, and flagellar elements promote biofilm development, which is important for cytotoxicity and pathogen survival. Lipopolysaccharides mediate septic shock through the release of cytokines and pyrogens.[16][21][22] Iron uptake during host invasion enhances the cytotoxicity and virulence of V vulnificus. Siderophores scavenge iron from transferrin and unbound iron, triggering sepsis and elevating mortality. Persons with conditions, eg, sickle cell anemia and hemochromatosis, characterized by elevated iron stores, are at increased risk of infection due to the promotion of bacterial growth.[13][23]

Three bacterial subtypes demonstrate significant clinical relevance. Type 1 represents the most prevalent strain and is primarily associated with sepsis. Type 2 occurs more frequently in eel farms and occasionally infects humans. Type 3 reportedly represents a hybrid of types 1 and 2 and causes severe infection, although the mortality rate remains below 8%.[2]

History and Physical

Clinical History

An affected person may have a recent history of swimming in warm, fresh, or salt water, skin contact with or consumption of shellfish, or even insect bites. Vibrio vulnificus must be included in the differential diagnosis for any infected wound sustained in or exposed to seawater or brackish water. Any beach or water-based activity, including shelling, fishing, scuba diving and snorkeling, and surfing, increases the risk of infection. A history of recent shellfish ingestion, especially raw oysters, should elevate suspicion of V vulnificus infection.[24] Chronic disease increases the morbidity and mortality of V vulnificus infection. A history of cirrhosis, hepatitis, hemochromatosis, sickle cell anemia, diabetes, cancers, or HIV or immunocompromise informs clinical decision-making in the care of an affected person.[25][26]

Infected persons may present with gastroenteritis, a wound infection, or sepsis. Up to 50% of persons presenting with V vulnificus infection may be septic upon initial presentation. Symptoms may be nonspecific, including fevers, chills, nausea, vomiting, diarrhea, abdominal pain, and myalgias. The symptoms may be self-limiting or may progress, sometimes rapidly. After the initial presentation, skin lesions may appear if not evident initially.

Physical Examination Findings

Signs of sepsis may be present at initial presentation or develop subsequently, including hypothermia or hyperthermia, tachycardia, tachypnea, hypotension, thrombocytopenia, altered mentation, and necrotizing skin infection.[2][27] Skin findings, including erythema, ecchymosis, bullae, often on the lower extremities, usually appear within 24 hours following V vulnificus ingestion. Frequently bilateral, skin lesions present as severe cellulitis with fluid-filled bullae that become hemorrhagic and progress rapidly to ulceration, necrotizing fasciitis with myonecrosis.[2] 

Skin findings from an infected wound are focal to the affected area, but may progress to an abscess, necrotizing infection, and sepsis.[3][27] A person with gastroenteritis following consumption of material infected with V vulnificus will present with focal or diffuse mild-to-moderate abdominal pain, possibly with a mild elevation in temperature, anorexia, nausea, and vomiting that spontaneously resolves. Less common manifestations of Vibrio vulnificus infection include keratitis, pneumonia, pyogenic spondylitis, meningoencephalitis, bacterial peritonitis, and endophthalmitis.[24]

Evaluation

Timely specimen collection is important for diagnosis, prognostic decision-making, and tracking treatment response. Important lab studies include blood, stool, and wound cultures, as well as labwork including complete blood count, comprehensive metabolic panel, lactic acid, coagulation panel, and, when indicated, arterial blood gas. An elevated white blood cell count with increased bands, abnormal clotting studies, decreased platelets, and increasing creatinine indicate systemic infection. Significantly depleted white count and hypothermia may indicate severe sepsis. An elevated creatine phosphokinase is associated with tissue necrosis, is an early indicator of sepsis, and can be used to monitor treatment efficacy.[28][29]

A culture may be negative even with bacteremia due to technical challenges in growing Vibrio vulnificus. Additional culture from an abscess, sputum, peritoneal fluid, and bullae can provide a rapid diagnosis. Other culture techniques include microarray methods that can detect multiple pathogens simultaneously. Recently, a rapid stool polymerase chain reaction assay that uses specimens from blood, wounds, or other tissues was introduced, capable of identifying all 3 Vibrionaceae (cholera, parahaemolyticus, and vulnificus) as well as a multitude of other enteric pathogens. The assay demonstrates nearly 100% sensitivity and specificity in detecting the Vibrio bacillus, and the quantitative data can be used to predict mortality. Elevated serum tumor necrosis factor α levels on admission correlate with higher mortality. Antibody serology can help monitor chronic infection, but this test is not useful in the early stages of disease.[2] Imaging, including ultrasound, computed tomography, and magnetic resonance imaging, helps further characterize necrotizing skin infections and identify soft-tissue gas and drainable collections.[2]

Treatment / Management

Early diagnosis and intervention are critical to the mitigation of morbidity and mortality associated with Vibrio vulnificus sepsis.[30] Sepsis protocol, including resuscitation, airway management, and pharmacologic support of perfusion, must be implemented promptly. Surgical intervention for necrotizing skin infections and myonecrosis has the greatest impact on morbidity and mortality if conducted within the first 12 hours of admission, and those with tissue necrosis not undergoing timely debridement have a very high mortality rate. Skin manifestations, eg, bullae, should be cultured, abscesses drained, and necrotic areas debrided. Topical antimicrobials (eg, 0.025% sodium hypochlorite or silver sulfadiazine) should be applied to infected skin.[13][31]

Any delay in culture data should not hinder the prompt administration of antibiotics. Persons who are septic on initial presentation and given appropriate antibiotics within 24 hours of admission have a mortality rate approaching 33%, and mortality is close to 100% when antibiotics are delayed beyond 72 hours. Antibiotic resistance has been found in up to 50% of Vibrio vulnificus infections, and empiric combination therapy is recommended.[32] In vitro studies have shown that third-generation cephalosporins, tetracyclines, carbapenems, fluoroquinolones, sulfa-trimethoprim, piperacillin-tazobactam, and aminoglycosides are all effective against V vulnificus. However, the CDC recommends combination therapy with intravenous ceftazidime and either a quinolone or a tetracycline.[33][34]

One effective antibiotic regimen consists of doxycycline 100 mg orally or intravenously twice daily for 1 to 2 weeks, combined with a third-generation cephalosporin, 1 to 2 g intravenously every 8 hours. Tigecycline, within the glycycline class, is effective against necrotizing fasciitis due to its high concentration in soft tissue and its ability to dampen the cytokine response. Ciprofloxacin can be added to achieve a higher antibiotic serum concentration.[2] Recommendations for children include a third-generation cephalosporin combined with doxycycline, ciprofloxacin, or trimethoprim-sulfamethoxazole with an aminoglycoside.[13]

Primary, limited gastroenteritis should be treated with fluid replacement, antipyretics, analgesics, and antiemetics. Hydration status, electrolyte levels, and renal function should be closely monitored and used to guide replacement therapy. The prevalence of antimicrobial resistance must be used to direct therapy. For example, in a recent study based in China, 67% of specimens exhibited resistance to multiple antibiotics and shared similar genetic profiles.[35] Current research activity is investigating novel drug targets and vaccine development against V vulnificus.[36][37]

Differential Diagnosis

The sudden onset of severe blistering and cellulitis may be seen in many clinical scenarios, including pemphigus, pemphigoid, Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, group A streptococcus, Pseudomonas, clostridial or Aeromonas infection, radiation exposure, scalding, or toxic ultraviolet exposure. Skin manifestations, particularly on bilateral lower extremities, following shellfish ingestion, suggest V vulnificus infection.[38][39]

A wide range of viral, bacterial, parasitic, and protozoan pathogens can cause acute infectious gastroenteritis. Viruses predominate, with noroviruses, rotaviruses, and adenoviruses accounting for many cases. Bacterial etiologies are the second most common, including Salmonella, Staphylococcus, Campylobacter, E coli, Bacillus cereus, Shigella, Yersinia, and Clostridium spp. C difficile is common in nursing homes. Protozoa Giardia lamblia, Entamoeba histolytica, and Cryptosporidium are responsible for a smaller percentage of cases. Finally, intestinal parasites, eg, Enterobius vermicularis, Ancylostoma duodenale, and Necator americanus, are all causative agents.[25][40] Noninfectious gastroenteritis is less common and may be related to conditions, eg, inflammatory bowel disease, irritable bowel syndrome, diabetes, and lactose intolerance, or secondary to medications (eg, non-steroidal anti-inflammatories or colchicine).[41]

Pertinent Studies and Ongoing Trials

The importance of a timely diagnosis, coupled with the challenges in obtaining accurate culture data, has prompted studies into new diagnostic technologies. Innovations include biosensor technology for use in seafood or water samples, involving transducers that can, using electrochemical or fluorescence, identify specific bacterial elements, eg, enzymes or nucleic acids. Next-generation DNA sequencing, particularly valuable in polymicrobial infections, can diagnose pathogens within 24 to 48 hours when standard cultures are negative. However, this method remains cost-prohibitive.[2]

Many experimental treatments are being evaluated for efficacy against Vibrio vulnificus. Examples include the antioxidant resveratrol, the anti-spasmodic otilonium bromide, the thiamine derivative fursultiamine hydrochloride, the citrus fruit derivative bergamottin, an inhibitor of cytochrome P4501A1, and mannitol. Additional therapeutic technologies under study include antimicrobial blue light at 450 nm that uses excitation of chromophores to promote the excitation of reactive oxygen species, and femtosecond laser therapy.[2]

Prognosis

Although the prevalence of Vibrio vulnificus infection remains low, the pathogen accounts for the highest number of seafood-related deaths in the United States.[14] The overall mortality rate for V vulnificus infection averages 35%. Patients with hepatic or immunosuppressive conditions experience markedly higher mortality, reaching 50% to 60%, compared with 16% among individuals without underlying disease. Sepsis carries an overall mortality rate of 50%, and cases complicated by hypotension often progress to poor outcomes.

Delays in antibiotic administration beyond 72 hours after admission raise mortality rates to nearly 100%. Elevated tumor necrosis factor α levels and positive polymerase chain reaction detection of V vulnificus serum DNA upon presentation also indicate poor prognosis. Patients with necrotizing fasciitis or myonecrosis who do not receive prompt surgical debridement face mortality rates approaching 100%. In contrast, V vulnificus skin infections produce an average mortality of 25%, while self-limiting gastroenteritis follows a more favorable clinical course.[2][7]

Complications

The major complications of V vulnificus infection are sepsis, necrotizing fasciitis, myonecrosis, and extremity gangrene and subsequent amputation. Necrotizing infection most commonly affects the limbs, but can involve the perineum and any tissue plane within the body. Systemic disease, eg, diabetes, malignancy, hepatic pathology, intravenous drug use, and immunosuppression, worsens the risk for the development of severe complications. Less common complications include meningoencephalitis, peritonitis, and pneumonitis.[42]

Consultations

Important consultants involved in the management of V vulnificus infections include specialists in infectious disease, general surgery, intensive care, dermatology, pharmacology, and possibly gastroenterology, cardiology, and cardiothoracic surgery.[30][43]

Deterrence and Patient Education

Health agencies must caution the public regarding the dangers of eating raw and undercooked seafood, especially raw oysters. The public should also be made aware of the increasing prevalence of this pathogen in marine environments, and all participants in recreational activities in proximity to at-risk waters should be informed through public notices and public health initiatives. Providing continuing education on this growing health risk is essential to promote adequate public awareness. Suspected and confirmed cases of Vibrio vulnificus are reportable to state health agencies. Given the high fatality rate of infection, prevention is crucial and involves a collaborative effort between health care practitioners, epidemiologists, regulatory agencies, and the public.[44][45]

Pearls and Other Issues

Global climate change has led to an increase in geographical regions conducive to Vibrio growth and expansion. Rising temperatures not only expand the range of waterborne and foodborne pathogens but also increase the frequency of hurricanes and other disasters, which contribute to disease outbreaks. Greater interface between humans and wildlife has increased human exposure to disease, resulting in potentially catastrophic outbreaks in endemic regions, and changing temperature and conditions create more suitable environments for growth in previously nonendemic areas. Vibrio bacteria rapidly proliferate in response to climatic changes and are often among the first pathogens to signal the clinical ramifications of regional climate change.[1] Known vectors for V vulnificus are generally found in marine environments. However, it has been demonstrated that bees can also uptake Vibrio when they come into contact with infected water, and the bacteria can be transferred to a human through a sting.[2] 

The severity of the clinical course is determined by the virulence factors of the pathogen rather than the overall quantity of bacteria. Antibiotic-resistant strains have been mounting. Studies of imported seafood have demonstrated that the bacteria have amassed resistance through genetic mutations, producing proteins that pump out or inactivate antibiotics, prevent binding, and employ other mechanisms to mitigate the efficacy of antibiotics across the treatment spectrum, including carbapenems and third and fourth-generation cephalosporins.[2] 

Enhancing Healthcare Team Outcomes

Vibrio vulnificus infection is a rapidly progressive, potentially fatal illness linked to contaminated seafood or exposure of open wounds to seawater. Although uncommon, the pathogen causes the majority of seafood-related deaths in the United States. Rising global temperatures and expanding coastal habitats have increased the bacterium’s prevalence and virulence. Individuals with hepatic disease, immunosuppression, or other chronic conditions face the greatest risk of severe outcomes, including necrotizing fasciitis, sepsis, and death within 24 to 48 hours of symptom onset. Early recognition and aggressive management remain essential to improving survival.[45]

Effective management of Vibrio vulnificus infection relies on strong interprofessional collaboration and timely decision-making. Physicians, general practitioners, and advanced practitioners must promptly identify high-risk presentations, initiate empiric antibiotic therapy, and coordinate surgical evaluation for necrotizing infections. Nurses monitor vital signs, wound progression, and treatment response while reinforcing patient education on prevention and early symptom reporting. Pharmacists ensure optimal antimicrobial selection and dosing to address emerging resistance. Coordinated communication among all healthcare professionals strengthens sepsis management, reduces diagnostic delays, and promotes patient-centered care that improves outcomes, enhances safety, and elevates team performance.

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

References

1.

Jayakumar JM, Martinez-Urtaza J, Brumfield KD, Jutla AS, Colwell RR, Cordero OX, Almagro-Moreno S. Climate change and Vibrio vulnificus dynamics: A blueprint for infectious diseases. PLoS Pathog. 2024 Dec;20(12):e1012767. [PMC free article: PMC11649097] [PubMed: 39680617]

2.

Candelli M, Sacco Fernandez M, Triunfo C, Piccioni A, Ojetti V, Franceschi F, Pignataro G. Vibrio vulnificus-A Review with a Special Focus on Sepsis. Microorganisms. 2025 Jan 10;13(1) [PMC free article: PMC11768060] [PubMed: 39858896]

3.

Leng F, Lin S, Wu W, Zhang J, Song J, Zhong M. Epidemiology, pathogenetic mechanism, clinical characteristics, and treatment of Vibrio vulnificus infection: a case report and literature review. Eur J Clin Microbiol Infect Dis. 2019 Nov;38(11):1999-2004. [PubMed: 31325061]

4.

Baker-Austin C, Oliver JD, Alam M, Ali A, Waldor MK, Qadri F, Martinez-Urtaza J. Vibrio spp. infections. Nat Rev Dis Primers. 2018 Jul 12;4(1):8. [PubMed: 30002421]

5.

Archer EJ, Baker-Austin C, Osborn TJ, Jones NR, Martínez-Urtaza J, Trinanes J, Oliver JD, González FJC, Lake IR. Climate warming and increasing Vibrio vulnificus infections in North America. Sci Rep. 2023 Mar 23;13(1):3893. [PMC free article: PMC10036314] [PubMed: 36959189]

6.

Bhat P, Bhaskar M, Sistla S, Kadhiravan T. Fatal case of necrotising fasciitis due to Vibrio vulnificus in a patient with alcoholic liver disease and diabetes mellitus. BMJ Case Rep. 2019 Jan 17;12(1) [PMC free article: PMC6340558] [PubMed: 30659010]

7.

Chuang PY, Yang TY, Huang TW, Tsai YH, Huang KC, Weng HH. Hepatic disease and the risk of mortality of Vibrio vulnificus necrotizing skin and soft tissue infections: A systematic review and meta-analysis. PLoS One. 2019;14(10):e0223513. [PMC free article: PMC6814278] [PubMed: 31652263]

8.

Brumfield KD, Chen AJ, Gangwar M, Usmani M, Hasan NA, Jutla AS, Huq A, Colwell RR. Environmental Factors Influencing Occurrence of Vibrio parahaemolyticus and Vibrio vulnificus. Appl Environ Microbiol. 2023 Jun 28;89(6):e0030723. [PMC free article: PMC10304686] [PubMed: 37222620]

9.

EFSA Panel on Biological Hazards (BIOHAZ). Koutsoumanis K, Allende A, Alvarez-Ordóñez A, Bolton D, Bover-Cid S, Chemaly M, De Cesare A, Herman L, Hilbert F, Lindqvist R, Nauta M, Nonno R, Peixe L, Ru G, Simmons M, Skandamis P, Baker-Austin C, Hervio-Heath D, Martinez-Urtaza J, Caro ES, Strauch E, Thébault A, Guerra B, Messens W, Simon AC, Barcia-Cruz R, Suffredini E. Public health aspects of Vibrio spp. related to the consumption of seafood in the EU. EFSA J. 2024 Jul;22(7):e8896. [PMC free article: PMC11263920] [PubMed: 39045511]

10.

Brumfield KD, Usmani M, Santiago S, Singh K, Gangwar M, Hasan NA, Netherland M, Deliz K, Angelini C, Beatty NL, Huq A, Jutla AS, Colwell RR. Genomic diversity of Vibrio spp. and metagenomic analysis of pathogens in Florida Gulf coastal waters following Hurricane Ian. mBio. 2023 Dec 19;14(6):e0147623. [PMC free article: PMC10746180] [PubMed: 37931127]

11.

Villicaña C, Amarillas L, Soto-Castro L, Gómez-Gil B, Lizárraga-Partida ML, León-Félix J. Occurrence and Abundance of Pathogenic Vibrio Species in Raw Oysters at Retail Seafood Markets in Northwestern Mexico. J Food Prot. 2019 Dec;82(12):2094-2099. [PubMed: 31724880]

12.

Lee SH, Lee HJ, Myung GE, Choi EJ, Kim IA, Jeong YI, Park GJ, Soh SM. Distribution of Pathogenic Vibrio Species in the Coastal Seawater of South Korea (2017-2018). Osong Public Health Res Perspect. 2019 Dec;10(6):337-342. [PMC free article: PMC6927416] [PubMed: 31897362]

13.

Yun NR, Kim DM. Vibrio vulnificus infection: a persistent threat to public health. Korean J Intern Med. 2018 Nov;33(6):1070-1078. [PMC free article: PMC6234401] [PubMed: 29898575]

14.

Baker-Austin C, Oliver JD. Vibrio vulnificus: new insights into a deadly opportunistic pathogen. Environ Microbiol. 2018 Feb;20(2):423-430. [PubMed: 29027375]

15.

Long D, Li M, Ma L, Huang J, Lv C, Chen Y, Cheng Z, Liu C, Huang H, Guo X, Yang C, Zhu Y. Epidemiological and genetic charateristics of Vibrio vulnificus from diverse sources in China during 2012-2023. Commun Biol. 2025 Jan 04;8(1):9. [PMC free article: PMC11700198] [PubMed: 39755764]

16.

Deeb R, Tufford D, Scott GI, Moore JG, Dow K. Impact of Climate Change on Vibrio vulnificus Abundance and Exposure Risk. Estuaries Coast. 2018 Dec;41(8):2289-2303. [PMC free article: PMC6602088] [PubMed: 31263385]

17.

Zaghi I, Tebano G, Vanino E, Vandi G, Cricca M, Sambri V, Fantini M, Di Antonio F, Terzitta M, Russo E, Cristini F, Bassi P, Biagetti C, Tatarelli P. Non-cholera Vibrio spp. invasive infections in the summer following May 2023 flood disaster in Romagna, Italy: a case series. Eur J Clin Microbiol Infect Dis. 2024 Jul;43(7):1469-1474. [PubMed: 38735888]

18.

Lu K, Li Y, Chen R, Yang H, Wang Y, Xiong W, Xu F, Yuan Q, Liang H, Xiao X, Huang R, Chen Z, Tian C, Wang S. Pathogenic mechanism of Vibrio vulnificus infection. Future Microbiol. 2023 Apr;18:373-383. [PubMed: 37158065]

19.

Oliver JD. The Biology of Vibrio vulnificus. Microbiol Spectr. 2015 Jun;3(3) [PubMed: 26185084]

20.

Heng SP, Letchumanan V, Deng CY, Ab Mutalib NS, Khan TM, Chuah LH, Chan KG, Goh BH, Pusparajah P, Lee LH. Vibrio vulnificus: An Environmental and Clinical Burden. Front Microbiol. 2017;8:997. [PMC free article: PMC5449762] [PubMed: 28620366]

21.

Duong-Nu TM, Jeong K, Hong SH, Puth S, Kim SY, Tan W, Lee KH, Lee SE, Rhee JH. A stealth adhesion factor contributes to Vibrio vulnificus pathogenicity: Flp pili play roles in host invasion, survival in the blood stream and resistance to complement activation. PLoS Pathog. 2019 Aug;15(8):e1007767. [PMC free article: PMC6748444] [PubMed: 31437245]

22.

Jung YC, Lee MA, Lee KH. Role of Flagellin-Homologous Proteins in Biofilm Formation by Pathogenic Vibrio Species. mBio. 2019 Aug 13;10(4) [PMC free article: PMC6692518] [PubMed: 31409687]

23.

Datta S, Kenton RJ. Characterization of temperature-dependent hemin uptake receptors HupA and HvtA in Vibrio vulnificus. Microbiologyopen. 2019 Oct;8(10):e905. [PMC free article: PMC6813434] [PubMed: 31290613]

24.

Kang SJ, Jung SI, Peck KR. Historical and Clinical Perspective of Vibrio vulnificus Infections in Korea. Infect Chemother. 2020 Jun;52(2):245-251. [PMC free article: PMC7335640] [PubMed: 32468743]

25.

Lin WP, Mu X, Chen SH, He CJ, Li HH, Sun CW, Bian HN, Lai W, Huang ZF. [Clinical characteristics of 11 patients with Vibrio vulnificus infection and the establishment of a rapid diagnosis procedure for this disease]. Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi. 2024 Mar 20;40(3):266-272. [PMC free article: PMC11630468] [PubMed: 38548397]

26.

Wang T, Huang Q. Vibrio vulnificus infection complicated by acute-on-chronic liver failure: A case report. Medicine (Baltimore). 2024 Oct 04;103(40):e39980. [PMC free article: PMC11460850] [PubMed: 39465726]

27.

Nolan B, Tien H, Haas B, Saskin R, Nathens A. The Rapid Emergency Medicine Score: A Critical Appraisal of Its Measurement Properties and Applicability to the Air Retrieval Environment. Air Med J. 2019 May-Jun;38(3):154-160. [PubMed: 31122578]

28.

Jiang J, Yang J, Mei J, Jin Y, Lu Y. Head-to-head comparison of qSOFA and SIRS criteria in predicting the mortality of infected patients in the emergency department: a meta-analysis. Scand J Trauma Resusc Emerg Med. 2018 Jul 11;26(1):56. [PMC free article: PMC6042435] [PubMed: 29996880]

29.

Sohn YW, Jang HY, Park S, Lee Y, Cho YS, Park J, Chung H, Kim SI. Validation of quick sequential organ failure assessment score for poor outcome prediction among emergency department patients with suspected infection. Clin Exp Emerg Med. 2019 Dec;6(4):314-320. [PMC free article: PMC6952629] [PubMed: 31910502]

30.

Pan Z, Guo X, Huang P, Duan L, Hong W, Xie YW, Li S. Early diagnosis and application of hemopurification combined with antibiotic therapy and surgical debridement for successful treatment of a child with Vibrio vulnificus necrotizing fasciitis and septic shock: a case report. BMC Infect Dis. 2025 Feb 27;25(1):286. [PMC free article: PMC11869408] [PubMed: 40016642]

31.

Myers CM, Miller JJ, Davis WD. Skin and Soft Tissue Infections: A Case of Necrotizing Fasciitis. Adv Emerg Nurs J. 2019 Oct/Dec;41(4):322-329. [PubMed: 31687996]

32.

Mok JS, Ryu A, Kwon JY, Park K, Shim KB. Abundance, antimicrobial resistance, and virulence of pathogenic Vibrio strains from molluscan shellfish farms along the Korean coast. Mar Pollut Bull. 2019 Dec;149:110559. [PubMed: 31543492]

33.

Kim SE, Shin SU, Oh TH, Kim UJ, Darboe KS, Kang SJ, Jang HC, Jung SI, Shin HY, Park KH. Outcomes of Third-Generation Cephalosporin Plus Ciprofloxacin or Doxycycline Therapy in Patients with Vibrio vulnificus Septicemia: A Propensity Score-Matched Analysis. PLoS Negl Trop Dis. 2019 Jun;13(6):e0007478. [PMC free article: PMC6590838] [PubMed: 31188821]

34.

Lee MT, Dinh AQ, Nguyen S, Krucke G, Tran TT. Late-onset Vibrio vulnificus septicemia without cirrhosis. Proc (Bayl Univ Med Cent). 2019 Apr;32(2):286-288. [PMC free article: PMC6541083] [PubMed: 31191157]

35.

Xu X, Liang S, Li X, Hu W, Li X, Lei L, Lin H. Antibiotic resistance and virulence characteristics of Vibrio vulnificus isolated from Ningbo, China. Front Microbiol. 2024;15:1459466. [PMC free article: PMC11330838] [PubMed: 39161608]

36.

Alotaibi BS, Ajmal A, Hakami MA, Mahmood A, Wadood A, Hu J. New drug target identification in Vibrio vulnificus by subtractive genome analysis and their inhibitors through molecular docking and molecular dynamics simulations. Heliyon. 2023 Jul;9(7):e17650. [PMC free article: PMC10336522] [PubMed: 37449110]

37.

Abbas G, Zafar I, Ahmad S, Azam SS. Immunoinformatics design of a novel multi-epitope peptide vaccine to combat multi-drug resistant infections caused by Vibrio vulnificus. Eur J Pharm Sci. 2020 Jan 15;142:105160. [PubMed: 31751777]

38.

Bross MH, Soch K, Morales R, Mitchell RB. Vibrio vulnificus infection: diagnosis and treatment. Am Fam Physician. 2007 Aug 15;76(4):539-44. [PubMed: 17853628]

39.

Campbell AM, Cabrera-Gumbau JM, Trinanes J, Baker-Austin C, Martinez-Urtaza J. Machine Learning Potential for Identifying and Forecasting Complex Environmental Drivers of Vibrio vulnificus Infections in the United States. Environ Health Perspect. 2025 Jan;133(1):17006. [PMC free article: PMC11756857] [PubMed: 39847704]

40.

Hasan H, Nasirudeen NA, Ruzlan MAF, Mohd Jamil MA, Ismail NAS, Wahab AA, Ali A. Acute Infectious Gastroenteritis: The Causative Agents, Omics-Based Detection of Antigens and Novel Biomarkers. Children (Basel). 2021 Dec 02;8(12) [PMC free article: PMC8700514] [PubMed: 34943308]

41.

Xu H, Liu Y, Niu H, Cai X, Zhan F. Characteristics, symptoms, and outcomes of patients with Vibrio vulnificus infection in Hainan, China: A retrospective study. Medicine (Baltimore). 2024 Nov 22;103(47):e40706. [PMC free article: PMC11596693] [PubMed: 39809157]

42.

Wong RMY, Chau LT, Mak MC, Tse WL, Ho PC. Necrotizing fasciitis induced by Vibrio vulnificus in patients without marine contact in Hong Kong. J Orthop Translat. 2019 Oct;19:151-154. [PMC free article: PMC6896480] [PubMed: 31844623]

43.

Radeva S, Vergiev S, Georgiev G, Niyazi D. Emerging Vibrio vulnificus-Associated Infections After Seawater Exposure-Cases from the Bulgarian Black Sea Coast. Medicina (Kaunas). 2024 Oct 24;60(11) [PMC free article: PMC11595927] [PubMed: 39596933]

44.

Walter K. What to Know About Vibrio vulnificus. JAMA. 2023 Mar 07;329(9):772. [PubMed: 36763351]

45.

Bell A, Bott M. Vibriosis:: What You and Your Patients Need To Know. Dela J Public Health. 2021 Jan;7(1):14-21. [PMC free article: PMC8352540] [PubMed: 34467175]

Disclosure: Anthony Haftel declares no relevant financial relationships with ineligible companies.

Disclosure: Mia Marietta declares no relevant financial relationships with ineligible companies.

Disclosure: Tariq Sharman declares no relevant financial relationships with ineligible companies.